BioSpace News Archive

According to a study published by the WHO, heart disease is one of the major causes of death in the world, with nearly 17.9 million of the population dying of the disease each year.

Increasing application of gelatin in treatment of aging skin and osteoarthritis, growing demand for gelatin-based nutrition supplements, and awareness regarding potential health benefits of gelatin are some key factors expected to drive revenue growth of the market.

Rapid growth of biopharmaceutical sector, growing demand for personalized medicine, and increasing research activities using humanized mice models are key factors driving revenue market growth.

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, today announced the completion of its acquisition of REMETRONIX. Terms of the transaction were not disclosed.

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that the Company’s leadership will participate in two upcoming conferences in January and February 2022.

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, announced that it had successfully completed the repricing of its existing credit facilities.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study (PRV-3279 EVAluation In Lupus- Phase 2).

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended December 31, 2021.

argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVGART™ intravenous infusion for the treatment of adult patients with generalized myasthenia gravis who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies.

Transgene and BioInvent International AB jointly announced the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.